Helimeds

Is Wegovy safe for weight loss?

Weight Loss6 min read
Dr. Alexandra Christiansen, MD

Medically reviewed by: Dr. Alexandra Christiansen, MD

Written by: Levan Maglakelidze

Fact Checked

Helimeds’ Fact-Checking Standards. Every piece of content at Helimeds adheres to the highest editorial standards for language, style, and medical accuracy. To learn what we do to deliver the best health insights to you, check out our content review principles.

Wegovy® can be a reasonable weight-loss treatment for people whose expected benefits outweigh the risks, but it is not safe for everyone. Common side effects include nausea, diarrhea and constipation. More serious problems can occur, and certain medical or family histories mean it should not be used.

The decision starts with a licensed provider reviewing your health history, medications and goals. If you are considering treatment, Helimeds offers a Wegovy pathway. A prescription is possible only if clinically appropriate after review and permitted in your state.

What Wegovy does and who it may help

Wegovy contains semaglutide, a medication that acts like a hormone involved in appetite regulation. It can help reduce hunger and is used alongside a reduced-calorie diet and increased physical activity.

In the United States, Wegovy is FDA-approved for weight management in adults with obesity and some adults with overweight who have a weight-related health condition. The injection is also approved for certain adolescents with obesity. A provider considers more than weight alone when deciding whether treatment is appropriate, including health history and potential risks. See UCHealth’s explanation of who may be considered for Wegovy.

Wegovy has helped people lose weight in clinical studies, although individual results vary. In one study described by the British Heart Foundation, adults receiving Wegovy and lifestyle support lost more weight on average than those receiving a placebo and the same lifestyle support. That benefit needs to be weighed against side effects and each person’s circumstances.

Common side effects

Digestive symptoms are among the most common side effects of Wegovy. Common side effects include:

  • Nausea and vomiting
  • Diarrhea or constipation
  • Stomach pain, bloating or indigestion
  • Headache and fatigue

These symptoms can be more noticeable when treatment begins or the dose increases. They may improve over time, but some people find them difficult to tolerate. Contact your provider if symptoms are persistent, severe or interfere with eating and drinking. Do not change your dose on your own.

Vomiting and diarrhea can lead to dehydration, which may cause kidney problems. The Wegovy safety information advises telling your provider right away if nausea, vomiting or diarrhea does not go away. Ask your provider what to do if you are having trouble keeping fluids down.

Serious risks and symptoms that need attention

Serious side effects are less common than digestive discomfort, but knowing what to look for matters. The manufacturer’s safety information describes several risks:

  • Pancreatitis: Severe stomach pain that does not go away, sometimes spreading to the back, can be a warning sign. Stop using Wegovy and call your provider right away.
  • Gallbladder problems: Upper abdominal pain, fever, yellowing of the skin or eyes, or clay-colored stools need prompt medical attention.
  • Serious allergic reaction: Stop using Wegovy and get medical help right away for symptoms such as swelling of the face, lips, tongue or throat, or trouble breathing or swallowing.
  • Low blood sugar: The risk is higher when Wegovy is used with certain diabetes medications, including insulin or sulfonylureas. Your provider can explain the signs to watch for and how to respond.
  • Vision changes: Tell your provider about changes in vision, particularly if you have type 2 diabetes. Sudden vision loss warrants urgent medical attention.

Not every symptom has a serious cause, but it is better to ask a clinician than to assume a new or worsening symptom is part of treatment.

Who should not use Wegovy?

Wegovy carries a boxed warning about thyroid C-cell tumors. Semaglutide caused these tumors in rodent studies; it is not known whether Wegovy causes them in humans.

Do not use Wegovy if you or a family member has had medullary thyroid carcinoma, a specific type of thyroid cancer, or if you have multiple endocrine neoplasia syndrome type 2, known as MEN 2. It should also not be used by someone who has had a serious allergic reaction to semaglutide or an ingredient in Wegovy. These restrictions are described in the manufacturer’s safety information.

Other conditions do not automatically answer the safety question, but they are important to discuss before treatment. Tell your provider if you have or have had:

  • Pancreatitis, gallbladder disease or kidney problems
  • Significant stomach or digestive problems
  • Type 2 diabetes, especially with a history of diabetic retinopathy
  • A planned surgery or procedure involving anesthesia or deep sedation

Bring a list of prescription and over-the-counter medications, vitamins and supplements. Wegovy should not be combined with another semaglutide-containing product or another GLP-1 receptor agonist. It also slows stomach emptying, which can affect how some medicines work.

If you are scheduled for a procedure, tell the team caring for you that you take Wegovy. The medication slows stomach emptying, and food or liquid entering the lungs during anesthesia or deep sedation has been reported in people taking GLP-1 receptor agonists. Your care team can advise you on the plan for your procedure.

Pregnancy and breastfeeding

Weight loss is not recommended during pregnancy. If you become pregnant while using Wegovy, stop using it and contact your provider promptly.

If you plan to become pregnant, discuss your plans before starting or continuing treatment. The Wegovy safety information says to stop Wegovy two months before a planned pregnancy. Also tell your provider if you are breastfeeding or plan to breastfeed. The considerations differ between the tablet and injection.

Is Wegovy safe to take long term?

Wegovy is intended for long-term weight management when it remains appropriate for the individual. Studies have followed participants for extended periods, but no medication can be considered risk-free indefinitely. A provider should periodically review your response, side effects, other health conditions and whether the treatment still makes sense for you. A review of Wegovy’s long-term safety notes that further long-term study can help clarify risks.

Some people regain weight after stopping treatment. That possibility is worth discussing before you start, along with how follow-up care, nutrition and physical activity fit into your plan. If you are considering stopping because of side effects or another concern, talk with your provider about your options.

Is compounded semaglutide the same as Wegovy?

No. Wegovy is an FDA-approved branded medication containing semaglutide. Compounded semaglutide is not FDA-approved and should not be described as interchangeable with Wegovy. Results from Wegovy studies do not establish how an individual compounded preparation will perform.

A provider can discuss whether a branded or compounded pathway is appropriate for your circumstances and whether it is available where you live. Whatever treatment you discuss, ask questions about the prescribed medication and how to use it. Medication fulfillment through Helimeds is handled by licensed pharmacy partners when treatment is prescribed.

How to decide on the next step

Wegovy’s safety depends on your health history, other medications and ability to follow up, as well as the potential benefits you hope to gain. Before a consultation, make a list of your conditions, medications, family thyroid cancer history, pregnancy plans and any questions about side effects.

To discuss the Helimeds Wegovy pathway, you can begin with a medical intake and consult with a licensed provider. If clinically appropriate, treatment may be prescribed and fulfilled through a licensed pharmacy partner, subject to state availability and medical review.

History

  1. Current Version

    Written by Levan Maglakelidze

    Medically reviewed by Dr. Alexandra Christiansen, MD